Literature DB >> 17393787

[Clinical efficacy and safety of recombinant human-growth hormone in the treatment of idiopathic asthenospermia].

Ting Chen1, Huai-jin Cheng.   

Abstract

OBJECTIVE: To evaluate the clinical efficacy and safety of recombinant human-growth hormone (rhGH) in the treatment of idiopathic asthenospermia.
METHODS: Forty patients with idiopathic asthenospermia were recruited, randomly divided into an rhGH group and a control group and treated for 3 months. In addition to routine treatment, the rhGH group (n = 18) received rhGH, while the control group (n = 18) underwent the routine treatment only. Before and after the treatment, semen samples were obtained, analyzed and graded according to the WHO laboratory manual, and the serum sexual hormone, thyroxin, liver and kidney function, blood cholesterol and blood glucose level were detected.
RESULTS: Sperm vitality was statistically increased, (28.60 +/- 32.89) % in the rhGH group and (8.42 +/- 25.87) % in the control (P < 0.01), and so was sperm (a + b) motility, (18.56 +/- 21.19) % in the rhGH group and (8.12 +/- 24.34) % in the control (P < 0.05).
CONCLUSION: rhGH can be used safely as an effective supplement to medicinal treatment of idiopathic asthenospermia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393787

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  1 in total

1.  The treatment effect of novel hGHRH homodimer to male infertility hamster.

Authors:  Xu-Dong Zhang; Xiao-Yuan Guo; Jing-Xuan Tang; Lin-Na Yue; Juan-Hui Zhang; Tao Liu; Yu-Xia Dong; Song-Shan Tang
Journal:  Korean J Physiol Pharmacol       Date:  2018-10-25       Impact factor: 2.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.